- Home
- MAIA
as 03-28-2025 12:58pm EST
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 44.8M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 126.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.46 - $5.99 | Next Earning Date: | 03-21-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Stan | MAIA | Director | Mar 3 '25 | Buy | $1.50 | 25,000 | $37,500.00 | 1,205,060 | |
| Guerrero Ramiro | MAIA | Director | Mar 3 '25 | Buy | $1.50 | 33,333 | $49,999.50 | 568,218 | |
| Smith Stan | MAIA | Director | Feb 24 '25 | Buy | $1.50 | 100,000 | $150,000.00 | 1,205,060 | |
| Guerrero Ramiro | MAIA | Director | Feb 24 '25 | Buy | $1.50 | 73,333 | $109,999.50 | 568,218 |
Latest MAIA Biotechnology Inc. News
MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
Business Wire
11 days ago
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
Business Wire
12 days ago
MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO
Business Wire
a month ago
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
Business Wire
a month ago
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
Business Wire
a month ago
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
Business Wire
a month ago
MAIA Biotechnology Announces Private Placement of $2,715,000
Business Wire
2 months ago
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
Compare MAIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.